key: cord-0858222-4jowmpmm
authors: Ludmir, Jonathan; Lu, Shu; Crowley, Jerome; Dalia, Adam; Shelton, Kenneth T
title: COVID Associated Myocardial Injury: Crossing the Threshold for Mechanical Circulatory Support
date: 2020-11-24
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2020.11.038
sha: abcae8e00e96095b77061357480c08b69f25f1d1
doc_id: 858222
cord_uid: 4jowmpmm

nan

The authors declare no competing interests.

Myocardial injury, or a troponin elevation above the 99 th percentile, 1 is common among hospitalized patients with coronavirus disease-2019 (COVID-19). In one large New York City cohort of 2,736 COVID patients, 36% had evidence of myocardial injury. 2 In this cohort, even minimal troponin I elevations (from >0.03 to 0.09 ng/ml) were significantly associated with death (HR 1.75; 95% CI: 1.37-2.24) while troponin I > 0.09 ng/ml had an even higher risk of mortality (HR 3.03; 95% CI 2.42 to 3.80). 2 However, myocardial injury is merely one complication of COVID related illness. Other mechanisms of cardiac dysfunction include type 1 MI, type 2 MI, vascular endothelial injury, embolic disease, and a systemic hyperinflammatory syndrome. 3 While optimal short term management strategies for COVID associated myocardial injury remain unclear, experience can be drawn from other infections and prior pandemics, such as influenza. The influenza virus illness, like COVID-19, is associated with elevated cardiac biomarkers, pericarditis, myocarditis, arrhythmias, and higher mortality. 4 In one H1N1 cohort of critically ill patients, troponin I was four times higher in patients who also developed acute respiratory distress syndrome. 5 Furthermore, influenza related myocarditis has been reported in 0.4-13% of patients, while autopsy data has demonstrated evidence of myocyte inflammation in necrosis in 30-50% of patients. 6 In this month's Journal, Hao Qian et al retrospectively reviewed early experience in one ICU in Wuhan, China. 7 The authors highlight the incidence of myocardial injury and its association with increased cardiovascular complications in the ICU, higher APACHE II scores, and overall mortality. The authors noted a 28-day mortality increase among patients with myocardial injury (HR-2.2, 95% CI 1.29-3.74; p=0.004). Myocardial injury in the setting of infection is not unique to COVID and has been studied in many systemic illnesses. 8 Elevated troponin occurred frequently in critically ill patients with influenza (H1N1) and resulted in longer ICU stay and higher mortality. 9 As we start to appreciate now that there is cardiac involvement in COVID-19 patients, Qian and colleagues have started the early process of studying myocardial markers. The pathobiologic mechanism of COVID-19 cardiac failure is not fully understood but certainly everything from stress induced catecholamine cardiomyopathy to cytokine storm are being considered. Future studies will likely focus on understanding the most likely molecular mechanisms leading to cardiac decline in order to start to understand possible future therapeutics. As we push forward focusing on vaccine development and possible therapeutics we are also able to use support strategies like ECMO and other advanced mechanical support devices for these critically ill patients.

The authors highlight the need for VV-ECMO in five of their ICU patients (two with myocardial injury).

The details surrounding decision making for VV-ECMO in this study are lacking. Additionally, VA-ECMO strategies were also not included in this study. While VA-ECMO outcome data in COVID-19 is still emerging, it is an important strategy in COVID related myocardial injury and shock. We can learn from the H1N1 experience. In one Australian and New Zealand cohort of critically ill H1N1 patients with ARDS, 68 patients were placed on VV-ECMO and 71% survived to ICU discharge. 10 Similarly, VA ECMO has been used intermittently with COVID. Data from the Extracorporeal Life Support Organization (ELSO) Registry recently identified 1035 COVID patients who required ECMO, of which 40 (4%) patients received VA-ECMO support. 12 Among the patients that required VA-ECMO support, 22 had clinical evidence of myocarditis. While data is still being analyzed for the ELSO cohort, about 40% of the entire ECMO cohort has been discharged alive. 12 In our experience VA-ECMO is an important tool available for severe COVID associated myocardial dysfunction and shock. VA ECMO may be considered for patients with refractory cardiogenic shock despite optimal medical therapies. Absolute contraindications include: active malignancy, BMI>40, unknown neurologic status, significant organ failure besides cardiopulmonary or renal, and severe chronic medical illnesses. While COVID forced our hospital and many others to be more conscious of distribution of resources, VA ECMO is and should be reserved for appropriate indications (Figure 1 ). While ECMO is not currently thought of as a "therapeutic" it does provide the hemodynamic and gas exchange capability to support end-organ function. In circumstances where patients improve with critical care and/or options exist in the form of durable mechanical devices (left ventricular assist devices) or possibly transplantation, ECMO provides the time and the physiologic bridge necessary to achieve these goals. As discussed in recent reviews the current pandemic has now proven that respiratory failure is just part of multiorgan failure in COVID-19. Our ability as anesthesiologists and critical care physicians to manage a second surge of COVID-19 critical illness will depend heavily on our ability to understand the molecular mechanisms of multiorgan failure. Successful treatment will also rely on our fundamental critical care knowledge and available support strategies like ECMO. 13 Early identification of myocardial injury among COVID patients is critical, as many are at risk for further cardiovascular compromise and collapse. Hao Qian and colleagues successfully illustrate the high prevalence of myocardial injury in a Wuhan cohort, many of whom developed severe cardiac complications. Mechanical circulatory support, in particular VA-ECMO, is an important strategy to consider in the management of COVID patients with severe cardiac dysfunction. 14 The use and success of VA and VV-ECMO in COVID-19 patients will most likely depend on the preparedness of the healthcare system as well as the ability for clinicians to identify patients who may require ECMO support for rapid assessment by a multidisciplinary ECMO team and possible transfer to specialized ECMO centers. 14 Lastly, while ECMO complications have been well-studied, we are just starting to understand the thromboembolic and hemostatic complications associated with COVID-19 ECMO patients compared to the incidence previously reported in non-COVID-19 ECMO patients. 15 This further highlights the importance of a dedicated cross-specialty and multidisciplinary critical care team to weigh the risks and benefits of ECMO on a case-by-case basis to ensure optimal patient care.

In conclusion, the pathophysiology of COVID-19 extends beyond the pulmonary system and can lead to significant myocardial injury. It can cause significant cardiovascular compromise warranting consideration for advanced therapies such as VA-ECMO in a subset of affected patients. Early identification of COVID patients in cardiopulmonary distress and a multidisciplinary critical care team to assess patients who have failed traditional medical therapy are crucial to ensure optimal care of the most critically ill COVID-19 patients.

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors

The cardiovascular manifestations of influenza: a systematic review

Right and left heart failure in severe H1N1 influenza A infection

Severe influenza: overview in critically ill patients

Myocardial Injury on Admission as a Risk in Critically Ill COVID-19 Patients: A Retrospective in-ICU Study

Viral Myocarditis-Incidence, Diagnosis and Management

Cardiac injury in patients with pandemic 2009 influenza A (H1N1) infection

Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome

When the heart gets the flu: Fulminant influenza B myocarditis: A case-series report and review of the literature

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Evolving Role of Anesthesiology Intensivists in Cardiothoracic Critical Care

Use of ECMO in Patients With Coronavirus Disease 2019: Does the Evidence Suffice? Journal of cardiothoracic and vascular anesthesia

A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19

Declarations of interest: none